Sexually transmitted diseases are increasing at an alarming rate. In 2023, 31,232 STI cases were reported in the United States. Syphilis cases in women increased from 10% (in 2014) to 30% (in 2023) in women. In addition, congenital syphilis cases increased by 44% in 2023. Therefore, researchers are emphasizing on developing high-quality and potent drugs to manage the disease effectively.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing syphilis pipeline development activities. Moreover, syphilis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Early stages of syphilis are treated with a benzathine penicillin (BPG) injection. It is also approved for pregnant women with syphilis. Antibiotics such as doxycycline, ceftriaxone or azithromycin can be used as a second-line treatment.
Key Questions Answered in the Syphilis - Pipeline Insight Report
This product will be delivered within 3-5 business days.
Report Coverage
The Syphilis Drug Pipeline Report by the publisher gives comprehensive insights into syphilis drugs currently undergoing syphilis clinical trials. It covers various aspects related to the details of each of these syphilis drugs under development for Syphilis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The syphilis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from syphilis.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing syphilis pipeline development activities. Moreover, syphilis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Syphilis Pipeline Outlook
Syphilis is a bacterial sexually transmitted infection (STI). It can be transmitted via pregnancy and blood transfusion as well. Although curable, it can lead to stillbirths in pregnancy, congenital syphilis in babies and neonatal deaths. Syphilis has three major phases. Primary phase lasts around 21 days and is characterised by the presence of a painless, round sore on the genitals. It may even go unnoticed and heal on its own. Secondary syphilis involves the occurrence of non-itchy rashes on feet, along with greyish lesions on moist areas. Lastly, latent syphilis has no symptoms. However, if left untreated can progress to the final stage after some years. The diagnosis is based on an individual's clinical history, lab tests and physical exams.Early stages of syphilis are treated with a benzathine penicillin (BPG) injection. It is also approved for pregnant women with syphilis. Antibiotics such as doxycycline, ceftriaxone or azithromycin can be used as a second-line treatment.
Syphilis Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of syphilis drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The syphilis therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Penicillins
- Tetracyclines
- Macrolides
- Cephalosporins
- Antibiotics
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Syphilis Pipeline Assessment Segmentation, By Phases
The syphilis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share of the total clinical trials for syphilis. There are around 13 drugs in phase IV of syphilis drugs.Syphilis Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under syphilis pipeline analysis include penicillins, tetracyclines, macrolides, cephalosporins and antibiotics. The treatment alternative depends on the stage of the disease, patient allergies, and multiple factors. Penicillins (administered through injections) remain the first-in-line treatment for various stages of syphilis. For penicillin-intolerant patients, other antibiotics are advised by healthcare providers.Syphilis Clinical Trials Therapeutic Assessment - Competitive Dynamics
The syphilis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in syphilis clinical trials:- Pfizer Inc.
- Sanofi
- GlaxoSmithKline (GSK)
- Merck & Co., Inc.
- Bayer AG
- Abbott Laboratories
- Hikma Pharmaceuticals
- Fresenius Kabi
Syphilis Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for syphilis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of syphilis drug candidates.Cefixime
The University of California, Los Angeles is conducting a study to examine an alternative treatment for syphilis infection. As a part of the study, oral cefixime will be administered to adult patients and they will be asked to visit the clinic 2 weeks after treatment initiation. They will undergo laboratory tests to assess ongoing symptoms.Linezolid
Currently in Phase 2 of a randomized, open-label, non-comparative, adaptive pilot trial, syphilis drug candidate Linezolid is under evaluation for its efficacy as an early syphilis treatment alternative. The participants will be asked to take part in follow-ups at an interval of 1, 3 and 6 months.Reasons To Buy This Report
The Syphilis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for syphilis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into syphilis collaborations, regulatory environments, and potential growth opportunities within syphilis pipeline insights.Key Questions Answered in the Syphilis - Pipeline Insight Report
- Which companies/institutions are leading the syphilis drug development?
- What is the efficacy and safety profile of syphilis pipeline drugs?
- Which company is leading the syphilis pipeline development activities?
- What is the current syphilis commercial assessment?
- What are the opportunities and challenges present in the syphilis drug pipeline landscape?
- What is the efficacy and safety profile of syphilis pipeline drugs?
- Which company is conducting major trials for syphilis drugs?
- Which companies/institutions are involved in syphilis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in syphilis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Syphilis
4 Patient Profile
5 Syphilis: Epidemiology Snapshot
6 Syphilis: Market Dynamics
7 Syphilis: Key Facts Covered
8 Syphilis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Syphilis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Syphilis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Syphilis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Syphilis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Syphilis, Key Drug Pipeline Companies
